Poly ICLC - Oncovir
Alternative Names: DNAJB1 PRKACA; Hiltonol; P.I.C.L.C.; Poly-ICLC; Polyinosinic polycytidylic acid; polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose; Polyriboinosinic-polyribocytidylic acidLatest Information Update: 30 Jan 2024
At a glance
- Originator Medical University of South Carolina; Oncovir
- Developer Abramson Cancer Center of the University of Pennsylvania; Augusta University; Bristol-Myers Squibb; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai; Immatics N.V.; Ludwig Institute for Cancer Research; Medical University of South Carolina; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); New York University School of Medicine; OncoQuest; Oncovir; Quest PharmaTech; Roswell Park Cancer Institute; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospitals of Geneva; University of Calgary; University of California, San Diego; University of Pittsburgh; Washington University School of Medicine
- Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
- Mechanism of Action 2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 protein modulators; Immunomodulators; Natural killer cell stimulants; Natural killer T cell stimulants; Proto oncogene protein c rel modulators; Proto oncogene protein c-ret modulators; Toll-like receptor 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Head and neck cancer; Malignant melanoma; Ovarian cancer; Sarcoma; Skin cancer; Solid tumours
- Phase I/II B-cell lymphoma; Breast cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; HIV infections; Non-Hodgkin's lymphoma; Peritoneal cancer
- Phase I COVID 2019 infections; Prostate cancer
- No development reported Acute myeloid leukaemia; Anaplastic astrocytoma; Chronic myelomonocytic leukaemia; Cytomegalovirus infections; Glioma; Influenza virus infections; Liver cancer; Malignant-mesothelioma; Myelodysplastic syndromes; Pancreatic cancer; Smallpox
Most Recent Events
- 23 Jan 2024 Finn in collaboration with A Glimmer of Hope Foundation and Breast Cancer Research Foundation plans a phase I trial for Adenocarcinoma (Adjuvant therapy) in USA (SC) (NCT06218303)
- 03 Oct 2023 Oncovir and VA Office of Research and Development plan the first-in-human phase Ib/II HAITEN-ICI trial for Non-small cell lung cancer (Late-stage disease, Combination therapy) in USA (IM, Injection) (Intratumoural, Injection), in December 2023 (NCT06064279)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Malignant-mesothelioma(In adolescents, In children, In adults) in USA (Intratumoural, Injection)